Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
Celldex plans to submit a biologics license application for barzolvolimab in 2027, based on full 52-week data from its Phase 3 chronic spontaneous urticaria studies. Executives shared the plan at Guggenheim’s 3rd Annual Healthcare Innovation Conference.
Why it matters — The planned filing timeline and the Phase 3 data supporting it are relevant to investors following Celldex’s barzolvolimab program.